EUVIMEDEUVIMED entdecken
Open Access

A dual-targeting approach with anti-IL10R CAR-T cells engineered to release anti-CD33 bispecific antibody in enhancing killing effect on acute myeloid leukemia cells

Zhifeng Yan, Runxia Gu, Haotian Ma, Nianci Chen, Ting Zhang, Yingxi Xu, Shaowei Qiu, Haiyan Xing, Kejing Tang, Zheng Tian, Qing Rao, Min Wang und 1 weitere

Cellular Oncology · 2024

DOI: 10.1007/s13402-024-00971-5 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cellular Oncology, 2024. Verfasst von Zhifeng Yan und 12 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin Key Laboratory of Cell Therapy for Blo…. Hauptthemen laut MEDLINE: Antibodies, Bispecific, Leukemia, Myeloid, Acute, Sialic Acid Binding Ig-like Lectin 3, Receptors, Chimeric Antigen. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, CAMS Innovation Fund for Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, BispecificLeukemia, Myeloid, AcuteSialic Acid Binding Ig-like Lectin 3Receptors, Chimeric AntigenHumansAnimalsCell Line, TumorT-LymphocytesImmunotherapy, AdoptiveReceptors, Interleukin-10Xenograft Model Antitumor AssaysMiceMice, Inbred NODCytotoxicity, Immunologic

Stichwörter der Autor:innen

AMLCD33Chimeric antigen receptorIL10RImmunotherapySecretion of T cell-redirecting bsAbs

Substanzen

Antibodies, BispecificSialic Acid Binding Ig-like Lectin 3Receptors, Chimeric AntigenReceptors, Interleukin-10CD33 protein, human

Autor:innen und Institutionen

  • State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematolo…
  • Tianjin Institutes of Health Science, Tianjin, 301617, China.
  • The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310006, China.
  • Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China.
  • Tianjin Institutes of Health Science, Tianjin, 301617, China. wangjxm@ihcams.ac.cn.
  • Tianjin Institutes of Health Science, Tianjin, 301617, China. wangjx@ihcams.ac.cn.

Förderung

  • National Key Research and Development Program of China
  • National Natural Science Foundation of China
  • CAMS Innovation Fund for Medical Sciences

Zitieren

APA

Yan, Z., Gu, R., Ma, H., Chen, N., Zhang, T., Xu, Y., Qiu, S., Xing, H., Tang, K., Tian, Z., Rao, Q., Wang, M., & Wang, J. (2024). A dual-targeting approach with anti-IL10R CAR-T cells engineered to release anti-CD33 bispecific antibody in enhancing killing effect on acute myeloid leukemia cells. Cellular Oncology. https://doi.org/10.1007/s13402-024-00971-5

Vancouver

Yan Z, Gu R, Ma H, Chen N, Zhang T, Xu Y, et al. A dual-targeting approach with anti-IL10R CAR-T cells engineered to release anti-CD33 bispecific antibody in enhancing killing effect on acute myeloid leukemia cells. Cellular Oncology. 2024. doi:10.1007/s13402-024-00971-5

BibTeX
@article{Yan2024,
  author = {Yan, Zhifeng and Gu, Runxia and Ma, Haotian and Chen, Nianci and Zhang, Ting and Xu, Yingxi and Qiu, Shaowei and Xing, Haiyan and Tang, Kejing and Tian, Zheng and Rao, Qing and Wang, Min and Wang, Jianxiang},
  title = {A dual-targeting approach with anti-IL10R CAR-T cells engineered to release anti-CD33 bispecific antibody in enhancing killing effect on acute myeloid leukemia cells},
  journal = {Cellular Oncology},
  year = {2024},
  doi = {10.1007/s13402-024-00971-5}
}
Kostenlos starten →